[CUSIP No. G21107100 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only) Jayhawk China Fund (Cayman), Ltd. (98-0170144) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [X] 3]
[CUSIP No. G21107100 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OFOVE PERSON(entities only) Jayhawk China Fund (Cayman), (98-0170144) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A (See Instructions) (a)[] (b)[X] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATIONyman Islands NUMBER OF SHARES]
[CUSIP No. G21107100 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OFOVE PERSON(entities only) Jayhawk China Fund (Cayman), (98-0170144) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A (See Instructions) (a)[] (b)[X] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATIONyman Islands NUMBER OF SHARES]
[China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011 HONG KONG, China, December 16, 2010 - China Cord Blood Corporation About China Cord Blood Corporation China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator]
[Chinard Bloodrporation to Hold Annual General Meeting in Hong Kong on February 18, 2011 HONG KONG, China, December 16, 2010 - Chinard Bloodrporationout Chinard Bloodrporation Chinard Bloodrporation is the first and largestrd blood banking operator in China in terms of geographicalverage and is the onlyrd blood banking operator with multiple licenses.Under the current government regulations,]
[_____________ SCHEDULE TO (Amendment No. 2) _____________ (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) _____________ CHINA CORD BLOOD CORPORATION (Name of Subject Company (Issuer) and Name of Filing Person (Issuer)) (Title of Class of Securities) KYG211071181 _____________________ ) _____________ Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong] [HONG KONG, China, December 13, - China Cord Blood Corporation Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, “We believe shareholders will appreciate our simplified capital structure. With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis. With all the stakeholders’ interests now]
[_____________ SCHEDULE TO (Amendment No. 2) _____________ (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) _____________ CHINA CORD BLOOD CORPORATION (Name of Subject Company (Issuer) and Name of Filing Person (Issuer)) (Title of Class of Securities) KYG211071181 _____________________ ) _____________ Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong] [HONG KONG, China, December 13, - China Cord Blood Corporation Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, “We believe shareholders will appreciate our simplified capital structure. With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis. With all the stakeholders’ interests now]
[_____________HEDULE TO (Amendment No. 2) _____________ (Rule 14d-100) Tender Offer Statement under Section14(d)(1) or 13(e)(1) _____________ CHINARD BLOODRPORATION (Name of Subjectmpany (Issuer) and Name of Filing Person (Issuer)) (Title of Class of Securities)G211071181 _____________________ ) _____________bert Chen +852 3605 8180bert.chen@chinacordbloodcorp.com 48th Floor, Bank of China Tower] [HONG KONG, China, December 13, - Chinard Bloodrporation Ms. Ting Zheng, Chairperson and CEO of Chinard Bloodrporationmmented, We believe shareholders will appreciate our simplifiedpital structure.With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis.Withl the stakeholders interests now fullyigned, we willntinue to]
[_____________HEDULE TO (Amendment No. 2) _____________ (Rule 14d-100) Tender Offer Statement under Section14(d)(1) or 13(e)(1) _____________ CHINARD BLOODRPORATION (Name of Subjectmpany (Issuer) and Name of Filing Person (Issuer)) (Title of Class of Securities)G211071181 _____________________ ) _____________bert Chen +852 3605 8180bert.chen@chinacordbloodcorp.com 48th Floor, Bank of China Tower] [HONG KONG, China, December 13, - Chinard Bloodrporation Ms. Ting Zheng, Chairperson and CEO of Chinard Bloodrporationmmented, We believe shareholders will appreciate our simplifiedpital structure.With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis.Withl the stakeholders interests now fullyigned, we willntinue to]
[China Cord Blood Corporation Reports Second Quarter and First Half Fiscal 2011 Financial Results 29.4% Increase in 2Q11 Revenue 24.6% Increase in 2Q11 Net Income Attributable to Shareholders Conference Call to be Held at 8 am ET November 24, 2010 HONG KONG, China, November 24, 2010 -- China Cord Blood Corporation (NYSE: CO) (“CCBC” or “the Company”), China’s leading provider]
